Why Patients and Doctors Love DSLT


Drop-free Alternative

Solve patient compliance



As Convenient as Prescribing Eye Drops


Ease of Use

Intuitive Set Up and Functionality


Treat More Patients

Improve Access to Care

Clinically Proven

A practice-changing technology allowing you to treat your patients efficiently and effectively.


Proof of Concept

Status: Completed 2014

Number of Patients: 28

Primary Endpoint: IOP reduction at 6 months

Read more


Status: Completed 2019

Number of Patients: 15

Primary Endpoint: IOP reduction at 3 months

Read more

GLAUrious – Multicenter Randomized
Controlled Study

Status: Enrollment Complete

Number of Patients: 192

Primary Endpoint: IOP reduction at 6 months

Follow-up: 12 months

Read more
DSLT in Focus

Understanding Energy Transmission

The understanding of energy transmission in SLT is changing. Recently confirmed in a literature review, the optimal energy needed for IOP reduction has not been established. The belief that IOP lowering occurs around the so-called 'Champaign bubble' level, has also not been verified. Read our topic paper to learn more.

Find a Distributor

Learn More


Download our brochure to
learn more.

BELKIN Vision Publications

2022 Journal of Glaucoma

Energy Dose-Response in Selective Laser Trabeculoplasty:
A Review

Radcliffe N, et al.

Read More

2021 TVST – ARVO Journal

Automated Direct Selective Laser Trabeculoplasty: First Prospective Clinical Trial

Goldenfeld M, et al.

Read More

2020 Biomedial Optics Express

Non-contact direct selective laser trabeculoplasty: light propagation analysis

Sacks Z, et al.

Read More

Get our latest news and updates!

Subscribe to receive BELKIN Vision's Newsletter with the latest news and clinical updates.

Skip to content